Magazine Article | December 1, 2022

Will The Finance And Funding Pendulum Swing Back To Black In 2023?

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

You know the story: 2022 has been a slow year for biopharma fundraising, M&As, and IPOs. But with valuations inching down and the 30 largest biopharma companies holding over $87 billion in cash reserves, strategic acquisitions may begin to pick back up next year, according to RSM, a financial services firm. Since necessity is the mother of invention, it’s also possible that more companies will explore alternative financing options — such as exchanging future product royalty streams for an up-front payment, crowdfunding, licensing technology, or manufacturing capacity — or getting prayers answered by an angel (investor). Clinical stage companies that manage to find a way to keep some fuel in the tank during the current downturn will be well positioned to hit the gas when economic conditions improve.

VIEW THE MAGAZINE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader